Magenta Therapeutics IncMagenta Therapeutics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This dashboard contains a questions and answers table about Magenta Therapeutics Inc. The page displays a zero-cost ESG report for Magenta Therapeutics Inc. The Disclosure score covers 17 United Nations Sustainable Development Goals including: 'Quality Education', 'Sustainable Cities & Communities' and 'Life below Water'.

Magenta Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.4; made up of an environmental score of 4.8, social score of 3.2 and governance score of 5.3.

SDG Transparency Score for Magenta Therapeutics Inc 
Low
0 - 3

4.4

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Magenta Therapeutics Inc 
4.8

Environmental

3.2

Social

5.3

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
1252Wntresearch AB
4.5
High
1252Verano Holdings Corp
4.5
High
1284Magenta Therapeutics Inc
4.4
High
1284Adinath Biolabs Ltd
4.4
High
1284Aligos Therapeutics Inc
4.4
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Magenta Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc offer flexible work?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Magenta Therapeutics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose water use targets?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Magenta Therapeutics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Magenta Therapeutics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Magenta Therapeutics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose its waste policy?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose energy use targets?

LockedSign up for free to unlock

Does Magenta Therapeutics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Magenta Therapeutics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Magenta Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sorry!

Failed to process!